received a letter from the New York regional office of the
Securities and Exchange Commission
notifying the company of an informal inquiry related to its clinical trials for Provenge and the attempt to get the prostate cancer vaccine cleared in the U.S.
The SEC's letter, dated July 3 and received July 9, says the investigation shouldn't be construed as an indication by the SEC or its staff that a violation of federal securities laws has occurred.
Dendreon plans to cooperate with the SEC staff and respond to a request for information. The company doesn't intend to comment on any aspect of the inquiry or possible outcomes until the probe has been completed.